Chronic Leukaemias Flashcards

1
Q

What are chronic leukaemias?

A

Increased proliferation of mature, ineffective cells in the bone marrow, peripheral blood and organs that are resistance to apoptosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How are chronic leukemias typically diagnosed?

A

Patients often have an incidental diagnosis, it is not always appropriate to initiate treatment straight away. The philidelphia chromosome is a key diagnostic, as it is a common abnormality of chronic leukaemia cancer cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is chronic Myeloid cancer?

A

A proliferative disorder from myeloid progenitor, leads to translocation of genetic material from chromosome 9-22 which forms the BCR-ABL oncogene on chromosome 22 (philadelphia chromosome) to increase tyrosine kinase activity which alters multiple signal pathways and causes malignant myeloid cell proliferation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How is chronic myeloid leukaemia treated?

A

Tyrosine kinase inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How do tyrosine kinase inhibitors work?

A

They bind to tyrosine kinase ATP specific binding site, which prevents tyrosine kinases from phosphorylating ATP and initiating the signalling cascade leading to cell proliferation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Give examples of tyrosine kinase inhibitors

A

imatinib, dasatinib, nilotinib, bosutinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Which factors affect initial treatment of chronic myeloid leukaemia?

A
  • EUTOS long term survivial score - higher the score means lower survival. If score is high, earlier discontinuation of treatment is desired.
  • co-morbidities and contraindications: nilotinib should be avoided in patients with prolonged QT interval/congestive heart failure, dasatinib should be avoided in pulmonary hypertension
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How is response to treatment measured in CML?

A
  • cytogenetic and molecular response rates
  • low bcr-abl transcript levels
  • less than 65% philadelphia chromosome positive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the duration of treatment for CML based on?

A

Individual patient parameters:

  • does the patient wish to get pregnant?
  • indefinite?
  • at least 5 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the adverse effects of TKIs?

A

Fatigue, insomnia, oedema, sub conjunctival haemorrhage

SCARS, rash, dry skin, alopecia, sweats, myalgia, cramp, GI effects, pancreatitis, bone marrow suppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What can be considered if patients have adverse effects to tki therapy?

A

Does reduction, antihistamines, topical steroids, corticosteroids, loperamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What must all patients have before starting tki?

A

CV risk assessment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How does resistance to TKI occur?

A

Drug efflux, drug binds to plasma proteins which leads to mutations in the gene and upregulation of an alternative signalling pathway (increased bcr-abl gene)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is chronic lymphocytic leukaemia and which patients is it common in?

A

A cancer of predominantly b cell origin, most common in older age, men and is incurable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is treatment of CLL based on?

A

Whether it is symptomatic, stage, age, cytogenetics. Treatment aims to induce remission and control symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How does treatment correlate to stage of CLL?

A

Stage A - watch and wait

Stages b&c - give treatment based on performance status, cytogenetics, morbidities and patient wishes

17
Q

How is early stage CLL (lymphocytes in blood/bone marrow) treated?

A
  • monitored very carefully
  • if nodal involvement/anaemia: treat and prolong life
  • young patients - intensive chemo
  • cyotoxic/easy to tolerate in elderly
18
Q

When should TKI be switched?

A

If a small increase in bcrabl gene is observed, keep same and increase dose
if significant resistance is observed, switch

19
Q

Why should you change TKI inhibitors?

A

If experiencing side effects or resistance

20
Q

How do you treat chronic Lymphocytic leukaemia?

A

Monoclonal antibodies aimed at T cells on cells involved in TP53 gene deletion as TP53 deletion drives CLL.